Cost effectiveness of palivizumab for respiratory syncytial virus prophylaxis in high-risk children: a UK analysis. (Q40256927)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17192118%20AND%20SRC:MED&resulttype=core&format=json

23 December 2019

title

Cost effectiveness of palivizumab for respiratory syncytial virus prophylaxis in high-risk children: a UK analysis (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17192118%20AND%20SRC:MED&resulttype=core&format=json

23 December 2019

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17192118%20AND%20SRC:MED&resulttype=core&format=json

23 December 2019

author name string

Mark J C Nuijten

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17192118%20AND%20SRC:MED&resulttype=core&format=json

23 December 2019

Wolfgang Wittenberg

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17192118%20AND%20SRC:MED&resulttype=core&format=json

23 December 2019

publication date

1 January 2007

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17192118%20AND%20SRC:MED&resulttype=core&format=json

23 December 2019

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17192118%20AND%20SRC:MED&resulttype=core&format=json

23 December 2019

volume

25

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17192118%20AND%20SRC:MED&resulttype=core&format=json

23 December 2019

issue

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17192118%20AND%20SRC:MED&resulttype=core&format=json

23 December 2019

page(s)

55-71

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17192118%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.2165/00019053-200725010-00006

23 December 2019

exact match

0 references

cites work

Prevention of respiratory syncytial virus (RSV) infection: RSV immune globulin intravenous and palivizumab. (American Academy of Pediatrics).

1 reference

Crossref

https://api.crossref.org/works/10.2165%2F00019053-200725010-00006

Respiratory syncytial virus infection

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.2165%2F00019053-200725010-00006

National Institute for Clinical Excellence and its value judgments

21 January 2018

1 reference

12 December 2020

Survival with congenital heart disease and need for follow up in adult life

1 reference

12 December 2020

Respiratory syncytial viral infection in infants with congenital heart disease

1 reference

12 December 2020

Asthma and immunoglobulin E antibodies after respiratory syncytial virus bronchiolitis: a prospective cohort study with matched controls

1 reference

12 December 2020

Ribavirin and bronchiolitis: variation in use in the UK.

1 reference

12 December 2020

Prevention of respiratory syncytial virus infections: indications for the use of palivizumab and update on the use of RSV-IGIV. American Academy of Pediatrics Committee on Infectious Diseases and Committee of Fetus and Newborn

1 reference

12 December 2020

Cost-effectiveness of respiratory syncytial virus prophylaxis among preterm infants

1 reference

12 December 2020

Reduction of respiratory syncytial virus hospitalization among premature infants and infants with bronchopulmonary dysplasia using respiratory syncytial virus immune globulin prophylaxis. The PREVENT Study Group

1 reference

12 December 2020

Impact of palivizumab on expected costs of respiratory syncytial virus infection in preterm infants: potential for savings

1 reference

12 December 2020

Respiratory syncytial virus immune globulin for prophylaxis against respiratory syncytial virus disease in infants and children with congenital heart disease. The Cardiac Study Group

1 reference

12 December 2020

Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. The IMpact-RSV Study Group

1 reference

12 December 2020

Health care utilisation of prematurely born, preschool children related to hospitalisation for RSV infection

1 reference

12 December 2020

Long-term consequences of respiratory syncytial virus (RSV) bronchiolitis

1 reference

12 December 2020

The selection of data sources for use in modelling studies

1 reference

12 December 2020

Ribavirin aerosol treatment of serious respiratory syncytial virus infection in infants

1 reference

12 December 2020

Morbidity and mortality after RSV-associated hospitalizations among premature Canadian infants

1 reference

12 December 2020

Health care utilisation of infants with chronic lung disease, related to hospitalisation for RSV infection

1 reference

12 December 2020

Hospitalisation for RSV infection in ex-preterm infants-implications for use of RSV immune globulin

1 reference

12 December 2020

Prophylactic administration of respiratory syncytial virus immune globulin to high-risk infants and young children. The Respiratory Syncytial Virus Immune Globulin Study Group

1 reference

12 December 2020

Palivizumab prophylaxis reduces hospitalization due to respiratory syncytial virus in young children with hemodynamically significant congenital heart disease

1 reference

12 December 2020

Respiratory syncytial virus infection in high risk infants and the potential impact of prophylaxis in a United Kingdom cohort

1 reference

12 December 2020

Does NICE have a cost-effectiveness threshold and what other factors influence its decisions? A binary choice analysis

1 reference

12 December 2020

Pediatric Investigators Collaborative Network on Infections in Canada (PICNIC) prospective study of risk factors and outcomes in patients hospitalized with respiratory syncytial viral lower respiratory tract infection

1 reference

12 December 2020

Respiratory syncytial virus and premature infants born at 32 weeks' gestation or earlier: hospitalization and economic implications of prophylaxis

1 reference

12 December 2020